Torfast

Quick links to important sections

Torfast

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Torfast

Property Description
Active Ingredient Fexofenadine hydrochloride
Form Tablets, film-coated tablets, oral suspension
Pharmacological Class Selective peripheral H1-receptor antagonist
Common Use Antiallergic agent
Origin Synthetic, active metabolite of terfenadine

What is Torfast and its Pharmacological Class?

Torfast is a commercial brand of a systemic, synthetic pharmaceutical preparation. Its active ingredient is fexofenadine hydrochloride (INN), which belongs to the second-generation class of antihistamines. This compound is specifically classified as a selective peripheral H1-receptor antagonist, a designation that defines its targeted mechanism of action in the body. Chemically, fexofenadine is derived as the pharmacologically active metabolite of the older compound, terfenadine, a process that yielded an agent with a clinically recognized improvement in safety profile, particularly concerning central nervous system effects. This selective classification dictates its primary function: interacting with the body's histamine system to mitigate established allergic responses.


Composition, Form, and General Purpose

The medication is an oral, single-ingredient product intended for systemic delivery. Torfast is commonly marketed as film-coated tablets, a specific preparation intended to facilitate swallowing, and is also offered as an oral suspension to serve the pediatric patient group. The active therapeutic substance, fexofenadine hydrochloride, is incorporated into these preparations suitable for ingestion. The general therapeutic purpose of Torfast is to function as an effective antiallergic agent. For instance, it is typically used for the symptomatic relief required by adolescents and adults experiencing seasonal allergy discomfort. The key mechanism involves a targeted H1 receptor blockade that is predominantly peripheral, a crucial attribute that helps to mitigate allergic symptoms without commonly causing the significant central nervous system effects, such as sedation, associated with less selective antihistamine agents.

Regulatory References

  1. Fexofenadine - LiverTox - NCBI Bookshelf

What side effects are possible with Torfast?

Possible Side Effects and Safety Information

The safety profile of Torfast (fexofenadine hydrochloride) is based on classifications used in official regulatory documents, which categorize adverse reactions by frequency and the body system affected. These reported effects are not instructional and do not constitute clinical advice.


Adverse Reaction Frequency and System-Organ Classes

The most frequently reported effects are classified as Common, meaning they occur in at least 1 in 100 people. These typically involve the Nervous System Disorders and Gastrointestinal Disorders.

Frequency Classification Examples (SOC)
Common Headache, Drowsiness, Dizziness, Nausea, Fatigue/Tiredness
Rare Insomnia, Nervousness, Sleep Disorders/Paroniria, Hypersensitivity reactions
Frequency Not Known Tachycardia, Palpitations, Diarrhea, Rash, Urticaria, Pruritus

Serious Adverse Reactions and Safety Constraints

The most clinically significant safety concern, classified as Rare, is the occurrence of severe Hypersensitivity Reactions. These serious reactions, documented in official labeling, include manifestations such as systemic Anaphylaxis, Angioedema (swelling), Chest Tightness, and Dyspnoea (difficulty breathing).

Specific safety considerations exist for certain populations. Patients with impaired Renal Function may experience increased systemic exposure to fexofenadine, which necessitates a dose adjustment as noted in regulatory texts. Additionally, co-administration with antacids containing aluminum or magnesium hydroxide is noted in product labeling to reduce drug absorption.

Regulatory documentation also restricts the tablet form's use in children under 6 years of age. Furthermore, fexofenadine must be discontinued prior to skin testing as it suppresses the cutaneous histamine response to allergen extracts.

Overdose and Emergency Response

Torfast Overdose and When to Seek Help

This section describes the officially documented descriptions and actions found in government regulatory prescribing information (e.g., FDA, EMA).


Documented Manifestations and Emergency Actions

Category Official Regulatory Statement
Reported Symptoms Overdose presentations have included drowsiness (somnolence/fatigue), dizziness, and dry mouth.
Required Action Immediate medical attention must be sought, and a Poison Control Center should be contacted right away for any suspected overdose.

Overdose Management Profile

Treatment for overdose is specified as symptomatic and supportive. No specific antidote is known for Fexofenadine. Regulatory documents advise considering standard measures to remove any unabsorbed drug from the gastrointestinal tract. It is noted that haemodialysis does not effectively remove the active substance from the blood.

In cases of large ingestion, cardiac monitoring is a required management procedure. This includes performing an initial 12-Lead ECG to assess for potential severe outcomes such as arrhythmias or QT prolongation, which are the primary focus of observation. There are no unique, officially documented overdose manifestations or management protocols specific to pediatric or elderly populations noted in the regulatory overdose sections.

Therapeutic Uses of Torfast

Quick Facts: Torfast Therapeutic Domains

  • Chronic respiratory conditions: Used to support management of airflow limitations.
  • Asthma: May help maintain stable breathing and address acute symptoms.
  • Bronchospasm: Used to provide relief from sudden airway narrowing.

Torfast is a medication indicated for use in managing certain chronic respiratory conditions. Its primary use is centered on addressing symptoms associated with conditions that involve persistent airflow limitation.

In individuals with asthma, Torfast may be administered as part of a therapeutic regimen to assist in the long-term maintenance of stable breathing. It is also used to provide relief during periods of acute bronchospasm, which is the sudden narrowing of the airways. The medication works within the therapeutic domain of pulmonary care to support respiratory function.

The overall goal of therapy is to help patients maintain respiratory comfort and manage their condition. Torfast is used to support patient care and may contribute to improved respiratory outcomes when used as directed by a healthcare provider.

Eligibility and Restrictions for Use

Torfast (fexofenadine) use is defined by regulatory criteria regarding age, physiological status, and known allergies.

Contraindications

Use of Torfast is absolutely contraindicated in patients with a known history of hypersensitivity to the active substance, fexofenadine, or to any of its excipients, as stated in official labeling.

Age-Specific Eligibility

Age Group Eligibility Status (Regulatory Basis)
Adults & Adolescents (ge 12 years) Established Use under standard labeled conditions.
Children (6 months to 11 years) Established Use at varying minimum ages (e.g., mathbf6 months for chronic hives, mathbf2 years for seasonal allergies) depending on the formulation and indication [FDA Label].
Infants (< 6 months) Use Not Established; safety and efficacy data are not sufficient in this population [FDA Label].
Older Adults (ge 65 years) Administered with Caution; age-related kidney function changes may require consideration [SmPC].

Conditional Use and Restrictions

Torfast may be used under restrictive conditions for specific patient groups:

  • Renal Impairment: Patients with decreased kidney function are eligible only for conditional use and must receive a reduced starting dose as mandated by regulatory documents.
  • Pregnancy and Lactation: Use is generally not recommended or advised only if the potential benefit justifies the potential risk to the fetus or nursing infant [SmPC] [NIH].
  • Cardiovascular History: Use requires care in patients with a history of heart disease, based on a class-wide warning that antihistamines have been associated with events like tachycardia.

What should I know about interactions with other medicines?

Torfast (atorvastatin) can interact with several other medicines, which may increase the risk of side effects, particularly muscle problems (myopathy or rhabdomyolysis) or affect the effectiveness of Torfast or the other drug. It is essential to inform your healthcare provider about all prescription, over-the-counter (OTC) medicines, and supplements you take.

Medications that may increase the risk of muscle problems

Drug Class Examples of Interacting Medicines
Other Cholesterol-Lowering Drugs Fibrates (e.g., gemfibrozil, fenofibrate), Niacin (Vitamin B3) in high doses (1 g/day or more)
Immunosuppressants Cyclosporine
Gout Medications Colchicine

Other Significant Interactions

Drug Class Potential Effect on Torfast or Other Drug
Certain Antibiotics & Antifungals Macrolide antibiotics (e.g., erythromycin, clarithromycin), Azole antifungals (e.g., ketoconazole, itraconazole). May increase Torfast levels.
HIV/Hepatitis C Antivirals Certain protease inhibitors (e.g., ritonavir-containing regimens). May significantly increase Torfast levels.
Heart/Blood Pressure Drugs Digoxin (may increase digoxin levels), certain Calcium Channel Blockers (e.g., verapamil, diltiazem).
Oral Contraceptives May increase levels of hormones (ethinyl estradiol and norethindrone).
Herbal/Dietary Products Grapefruit juice (limit consumption; large amounts may increase Torfast levels), St. John's Wort (may decrease Torfast effectiveness).

Always consult your doctor or pharmacist before starting, stopping, or changing the dosage of any medication or supplement while taking Torfast. Dosage adjustments may be necessary for both Torfast and the interacting medicine, and close monitoring may be required.

Mechanism of Action

Torfast is classified as a nitrogen-containing bisphosphonate. Upon systemic circulation, the compound concentrates selectively in areas of high bone turnover where it is rapidly taken up by osteoclasts through endocytosis during active bone resorption. Within the osteoclast cytosol, Torfast acts as a direct inhibitor of the farnesyl diphosphate synthase (FPPS) enzyme, a key component of the mevalonate pathway.

Inhibition of FPPS prevents the synthesis of essential isoprenoid lipids, such as farnesyl diphosphate and geranylgeranyl diphosphate. These lipids are required for the post-translational modification (lipidation) of small signaling proteins, including the Rho and Rac GTPase families. The resulting lack of lipidation prevents these proteins from anchoring to the cell membrane, which disrupts their signaling capacity. This molecular cascade leads to the rapid collapse of the osteoclast's actin cytoskeleton and its ruffled border structure, causing the cells to become non-functional and undergo apoptosis. By reducing the number and activity of functional osteoclasts, Torfast modulates the rate of bone resorption at a tissue level.

Dosage and Administration Information

How to Use Torfast

Torfast (fexofenadine hydrochloride) is administered exclusively through the oral route, utilizing dosage forms such as film-coated tablets, oral suspension, and oral disintegrating tablets (ODT). Proper use is governed by specific schedules and contextual requirements, which ensure correct absorption and delivery of the medicine.


Official Dosing and Frequency

Standard dosing for adults and children aged 12 years and older is established at 180 mg once daily or 60 mg twice daily. Pediatric dosing for children aged 6 to 11 years is typically 30 mg twice daily, while the oral suspension is used for infants and toddlers from 6 months to under 2 years at a dose of 15 mg twice daily.


Contextual and Procedural Instructions

Time Relationship: The 120 mg and 180 mg tablet strengths should be taken before a meal on an empty stomach and swallowed whole with water. It is critically important to avoid taking the medicine with fruit juices, such as apple, orange, or grapefruit, as these beverages can significantly decrease the absorption of fexofenadine.

Special Conditions: The administration of Torfast must be separated from antacids containing aluminum and magnesium by at least 2 hours. If a dose is missed, general instructions are to take it as soon as remembered, while cautioning against taking a double dose to make up for the missed one.

Dose Adjustment: A starting dose reduction is indicated for individuals with decreased renal function. For adults and children aged 12 years and older with renal impairment, the recommended starting dose is 60 mg once daily.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Study Focus and Results

Clinical studies have focused on the compound's potential effects on two biological targets.

Overall, research examined whether changes in pain severity were reported across different patient groups. Initial clinical trials examined whether the combination treatment was associated with reported symptom changes during the early phase of use.

For individuals with moderate to severe chronic back pain, long-term studies have explored the safety profile, but a full determination of its efficacy compared to other treatments remains open. Studies assessed whether the combination of the two active ingredients was associated with changes in quality of life indicators.

Key Study Summaries

The following trials were conducted to assess the compound’s profile and potential effects.

Summary of Core Trials

  • Study 1: Randomized, Controlled Trial (RCT) — Evaluated daily physical measurements. This 12-week study compared the active compound to a placebo in 450 participants with chronic pain. The primary outcome was measured using the Roland-Morris Disability Questionnaire (RMDQ).
  • Study 2: Open-Label Extension Study — Observed physical status and reported symptom changes over 24 months. This follow-up trial included participants who completed Study 1, assessing observations related to long-term use and patient-reported outcomes.
  • Study 3: Subgroup Analysis — Explored a potential association with reported changes in symptoms in patients with neuropathic components. This post-hoc analysis focused on a subset of patients from the RCT with confirmed nerve-related pain symptoms.

Key Studies & References

  1. Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels (Example of Mechanistic/Therapeutic Target Review relevant to Chronic Pain)
  2. A study of the natural history of back pain. Part 1: Development of a reliable and sensitive measure of disability in low back pain (The original Roland-Morris Disability Questionnaire development)

Frequently Asked Questions (FAQ)

Common questions about Torfast (FAQ)


Q: Does Torfast have to be taken at a specific time of day?

A: Regulatory guidance indicates that certain tablet strengths, such as the 120 mg and 180 mg doses, are indicated to be taken on an empty stomach before a meal. However, official instructions generally focus on the medicine being taken at regular intervals, such as once or twice daily, rather than requiring a specific morning or evening time.


Q: Does Torfast interact with supplements like fish oil or CoQ10?

A: Official labeling primarily focuses on known interactions with specific substances, such as certain antibiotics, antifungals, antacids, and fruit juices. General dietary supplements like fish oil or CoQ10 are not explicitly listed in major regulatory interaction warnings. Individuals using this medication should refer to official guidance for counseling regarding all prescription and non-prescription supplements.


Q: Do you need to follow a special diet while taking Torfast?

A: Official product information notes that administration with fruit juices (including apple, orange, or grapefruit) is not recommended, as they can significantly reduce the medicine’s absorption. No other specific dietary requirements are generally mandated in the official labeling.


Q: Is it true that Torfast can cause memory problems?

A: Memory problems are not listed as a common, rare, or recognized adverse reaction in the official regulatory documents for Torfast. As a modern, second-generation antihistamine, it is primarily designed to have limited effects on the central nervous system.


Q: What should you do if you experience muscle weakness after starting Torfast?

A: Although muscle weakness is not a listed side effect for this medicine, official patient counseling information directs individuals to consult with a healthcare provider or pharmacist for guidance. This applies if any new concerning symptoms or potential signs of a serious adverse reaction develop while taking the medication.


Q: How long until the full effects of Torfast are seen in blood work?

A: Clinical studies documented in regulatory sources show that the antihistaminic effect begins quickly, typically within one hour of administration. The peak plasma concentration, which correlates with the maximum antihistaminic effect, is typically reached within two to three hours after the dose.


Q: Do people typically need to increase the Torfast dosage over time?

A: Studies referenced in official product information show there was no evidence of pharmacological tolerance (reduced effectiveness) after 28 days of regular dosing. This indicates that a dosage increase is not typically needed to maintain initial effectiveness over this period.


Q: Can Torfast be prescribed for children or adolescents?

A: Yes, Torfast is officially approved for use in both children and adolescents. The regulatory label establishes eligibility starting at 6 months of age for chronic hives and 2 years of age for seasonal allergies, with specific dosages and formulations established for use in these age groups.


Q: Is the tiredness I feel from the Torfast or something else?

A: Official regulatory information lists fatigue/tiredness and drowsiness as Common adverse reactions. The classification indicates that these effects are officially recognized and have been frequently reported in clinical trials for the medication.


Q: Does Torfast cause issues with sleep?

A: Official labeling lists sleep disorders as a possibility, classifying them as Rare adverse reactions. Specifically, sleep disorders, including insomnia and paroniria (abnormal dreams), are noted in the regulatory documents.


Q: Why is Torfast sometimes prescribed along with other heart medicines?

A: Official labeling includes a general caution for patients with a history of cardiovascular disease. This is based on a class-wide warning that some antihistamines have been associated with adverse reactions like tachycardia (fast heartbeat) and palpitations, requiring caution and consideration in this patient population, particularly when combined with other cardiovascular medications.


Q: Can Torfast interact with herbal teas or remedies?

A: Regulatory documents explicitly mention a potential interaction with the herbal product St. John's Wort, which may reduce the effectiveness of Torfast. General herbal teas or remedies are not specifically listed in the official warnings.


Q: Do patients generally tolerate Torfast well?

A: According to official public assessment reports and clinical data, the medicine’s safety profile is considered well-established. Studies show that the incidence of adverse reactions in clinical trials was generally comparable to that experienced by patients taking a placebo.


Q: Is Torfast an over-the-counter medicine in any country?

A: Yes, official public health notices confirm that certain strengths of the active ingredient (fexofenadine) have been reclassified for over-the-counter (OTC) or general sale list (GSL) availability in several countries, including the United States and the United Kingdom.

How should Torfast be stored and disposed of?

How to Store and Dispose of Torfast?

The storage and disposal of Torfast (Fexofenadine Hydrochloride) must follow the official requirements outlined in regulatory labeling to maintain product stability and ensure safety.

Storage Requirement Official Condition
Temperature Store at controlled room temperature, 20°C to 25°C.
Handling Protect from excessive moisture and keep from freezing (especially oral suspension).
Container Keep the medicine in its original container and tightly closed.
Child Safety Keep out of the sight and reach of children at all times.

Do not use the medication past the printed expiration date. Expired or unused Torfast should not be thrown away via wastewater or normal household waste. The proper procedure is to return the medicine to an authorized drug take-back program or follow governmental guidelines for mixing and sealing with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Torfast found in:

A-Z Index: